- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07760909
Metabolic Flux Analysis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Metabolic Flux Analysis in MASLD
Przegląd badań
Status
Warunki
Szczegółowy opis
MASLD and its progressive form MASH are associated with obesity, insulin resistance, altered hepatic substrate delivery, and changes in mitochondrial metabolism. However, the direction and significance of hepatic citric acid cycle flux changes in human MASLD remain unresolved. This study will apply in vivo metabolic flux analysis using non-radioactive stable isotope tracers to quantify hepatic and extrahepatic metabolic pathway activity in bariatric surgery participants before and after surgery.
Participants will complete three study timepoints. Approximately one week before surgery, participants will undergo fasting physical measurements, questionnaires, research blood collection, and abdominal MRI/MRE to quantify liver fat and stiffness. On the day of surgery, participants will receive intravenous infusions of [¹³C₃]lactate, [6,6-²H₂]-D-glucose, and [9,9-²H₂]palmitate for approximately 120 minutes with serial blood collection. During the clinically planned bariatric surgery, research tissue specimens may be collected from liver, omentum, subcutaneous adipose tissue, and skeletal muscle only if the surgeon determines collection can be performed safely without interfering with clinical care. Approximately 6 months after surgery, participants will repeat fasting physical measurements, questionnaires, MRI/MRE, stable isotope tracer infusion, and blood collection; no follow-up tissue biopsies will be collected.
Isotope enrichment patterns in plasma metabolites and tissue metabolites will be analyzed by mass spectrometry and modeled using metabolic flux analysis software to estimate hepatic citric acid cycle flux, gluconeogenesis, glucose turnover, free fatty acid turnover, lactate turnover, and selected extrahepatic metabolic fluxes. Liver fat and stiffness will be assessed by MRI/MRE, and intraoperative liver tissue will be scored for MASLD/MASH features using established histologic criteria.
Typ studiów
Zapisy (Szacowany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Charles R Flynn, PhD
- Numer telefonu: 615-343-8329
- E-mail: MASLD.research@vumc.org
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Opis
Inclusion Criteria:
- Scheduled and clinically cleared for protocol-eligible bariatric surgery at Vanderbilt University Medical Center.
- BMI ≥40 kg/m², or BMI >35 kg/m² with at least one obesity-associated comorbidity, such as type 2 diabetes, cardiovascular disease, hypertension, hyperlipidemia, obstructive sleep apnea, MASLD, osteoarthritis, or polycystic ovarian syndrome.
- Able and willing to complete study procedures, including informed consent, questionnaires, blood draws, MRI/MRE imaging, stable isotope tracer infusion, and research tissue collection during planned bariatric surgery.
- Able to provide informed consent in English.
Exclusion Criteria:
- Contraindication to MRI/MRE, including implanted cardiac defibrillator, pacemaker, or other MRI-incompatible implanted device.
- Prior gastric or intestinal surgery, pancreatic surgery, or other prior surgery that, in the judgment of the study team or bariatric surgeon, would interfere with study procedures or outcome interpretation.
- Active cancer or ongoing cancer treatment.
- Presence or history of HIV infection.
- Alcohol use above study-defined limits: more than 14 alcoholic drinks per week for men or more than 7 alcoholic drinks per week for women, or illicit drug use that would interfere with safe participation or interpretation of study results.
- Anemia or other hematologic condition that would increase risk from study blood collection.
- Abnormal ECG or clinically significant cardiovascular finding that would increase risk from study procedures.
- Impaired renal function or other clinically significant condition that would increase risk from study participation.
- Known Wilson's disease, alpha-1 antitrypsin deficiency, hemochromatosis, or other non-MASLD chronic liver disease that would confound interpretation of study outcomes.
- Any medical, surgical, or safety condition that, in the judgment of the PI, clinical co-investigator, CRC staff, anesthesia team, or bariatric surgeon, would make participation unsafe or interfere with completion of study procedures.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Podstawowa nauka
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Bariatric Surgery Participants Undergoing Metabolic Flux Assessment
Adults scheduled and clinically cleared for protocol-eligible bariatric surgery at VUMC will undergo research MRI/MRE, blood collection, non-radioactive stable isotope tracer infusions, and intraoperative research tissue collection during planned bariatric surgery, followed by repeat noninvasive metabolic assessment approximately 6 months after surgery.
|
Clinically indicated bariatric surgery, such as Roux-en-Y gastric bypass or sleeve gastrectomy, performed as part of standard clinical care.
Inne nazwy:
Intravenous non-radioactive stable isotope tracers administered for research measurement of metabolic flux: [¹³C₃]lactate, [6,6-²H₂]-D-glucose, and [9,9-²H₂]palmitate.
Abdominal MRI proton density fat fraction and magnetic resonance elastography to assess hepatic fat and stiffness before surgery and approximately 6 months after surgery.
Inne nazwy:
Liver, omentum, subcutaneous adipose tissue, and skeletal muscle specimens collected only during clinically planned bariatric surgery and only if safe in the surgeon's judgment.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in hepatic citric acid cycle flux after bariatric surgery
Ramy czasowe: Baseline/day of surgery to approximately 6 months post-surgery
|
Change in hepatic citric acid cycle flux estimated from stable isotope enrichment patterns, including [¹³C₃]lactate-based measurements, before bariatric surgery and approximately 6 months after surgery.
|
Baseline/day of surgery to approximately 6 months post-surgery
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in hepatic gluconeogenic flux
Ramy czasowe: Baseline/day of surgery to ~6 months
|
Estimated from plasma glucose isotope enrichment and metabolic flux modeling
|
Baseline/day of surgery to ~6 months
|
|
Change in endogenous glucose production
Ramy czasowe: Baseline/day of surgery to ~6 months
|
Estimated using [6,6-²H₂]-D-glucose tracer dilution
|
Baseline/day of surgery to ~6 months
|
|
Change in free fatty acid turnover
Ramy czasowe: Baseline/day of surgery to ~6 months
|
Estimated using [9,9-²H₂]palmitate tracer dilution
|
Baseline/day of surgery to ~6 months
|
|
Change in lactate turnover / lactate-related flux
Ramy czasowe: Baseline/day of surgery to ~6 months
|
Estimated using stable isotope enrichment patterns
|
Baseline/day of surgery to ~6 months
|
|
Liver fat by MRI-PDFF
Ramy czasowe: Baseline to ~6 months
|
Hepatic fat fraction quantified by MRI-PDFF
|
Baseline to ~6 months
|
|
Liver stiffness by MRE
Ramy czasowe: Baseline to ~6 months
|
Liver stiffness quantified by magnetic resonance elastography
|
Baseline to ~6 months
|
|
Histologic MASLD/MASH severity
Ramy czasowe: Intraoperative baseline only
|
Liver biopsy scored for steatosis, inflammation, ballooning, fibrosis, and MASLD activity score
|
Intraoperative baseline only
|
|
Extrahepatic metabolic fluxes
Ramy czasowe: Intraoperative baseline only
|
Metabolic fluxes in skeletal muscle, omentum, and subcutaneous adipose tissue estimated from intraoperative tissue specimens
|
Intraoperative baseline only
|
|
Serum inflammatory markers
Ramy czasowe: Baseline/day of surgery; possibly ~6 months if collected
|
Research measurement of inflammatory markers including CRP, cytokines, adhesion molecules, and related biomarkers
|
Baseline/day of surgery; possibly ~6 months if collected
|
|
Metabolic hormone profile
Ramy czasowe: Baseline/day of surgery; possibly ~6 months if collected
|
Insulin, leptin, C-peptide, GLP-1, GIP, PYY, ghrelin
|
Baseline/day of surgery; possibly ~6 months if collected
|
|
Bile acid profile
Ramy czasowe: Baseline/day of surgery; possibly ~6 months if collected
|
Bile acids measured by LC-IM-MS
|
Baseline/day of surgery; possibly ~6 months if collected
|
Współpracownicy i badacze
Śledczy
- Główny śledczy: Charles R Flynn, PhD, Vanderbilt University Medical Center
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Zaburzenia odżywiania
- Przekarmienie
- Masy ciała
- Choroby Układu Pokarmowego
- Choroby wątroby
- Nadwaga
- Stany patologiczne, oznaki i objawy
- Choroby żywieniowe i metaboliczne
- Objawy i symptomy
- Otyłość
- Tłusta wątroba
- Lecznictwo
- Techniki i procedury diagnostyczne
- Diagnoza
- Procedury chirurgiczne, operacyjny
- Tomografia
- Obrazowanie diagnostyczne
- Ultrasonografia
- Bariatria
- Zarządzanie otyłością
- Obrazowanie rezonansu magnetycznego
- Chirurgia bariatryczna
- Techniki obrazowania elastyczności
Inne numery identyfikacyjne badania
- 260832
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Ramy czasowe udostępniania IPD
Typ informacji pomocniczych dotyczących udostępniania IPD
- PROTOKÓŁ BADANIA
- SOK ROŚLINNY
- ICF
- CSR
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .